Colorectal cancer and rectal cancer
Research activity includes metastatic colorectal cancer, colon cancer, and upper rectal cancer, with attention to molecularly defined subgroups such as BRAF V600E-mutated and KRAS G12C-mutated disease, as well as microsatellite instability and microsatellite stable tumors.
- Targeted therapy in advanced colorectal disease
- Immunotherapy for biomarker-selected colorectal cancer
- Neoadjuvant and adjuvant treatment strategies
The portfolio also covers liver-dominant metastasis and postoperative management in older patients with resected disease.
Gastric, oesophageal, and gastro-oesophageal junction adenocarcinoma
Trials focus on advanced oesogastric adenocarcinoma, stomach cancer, and gastro-oesophageal junction adenocarcinoma, including disease that progresses after peri-operative treatment or presents with metastatic spread.
- First-line systemic therapy for advanced upper gastrointestinal cancer
- Anti-angiogenic therapy in metastatic gastric disease
- Immune checkpoint inhibition in recurrent adenocarcinoma
Work in this area also extends to treatment options for patients with older age and advanced disease burden.
Pancreatic cancer
The sponsor supports studies in borderline resectable pancreatic adenocarcinoma and metastatic pancreatic cancer, with interest in both perioperative and systemic treatment settings.
- Neoadjuvant chemotherapy for borderline resectable disease
- Combination chemotherapy in metastatic pancreatic adenocarcinoma
- Biomarker-guided treatment selection
Research activity reflects a focus on treatment choices for pancreatic tumors with high clinical complexity and limited surgical options.
Hepatobiliary and liver-related cancers
Clinical research includes hepatocellular carcinoma, biliary tract carcinoma, and intrahepatic cholangiocarcinoma, with additional studies in colon cancer with liver metastasis.
- Adjuvant therapy in resected biliary tract cancer
- Systemic treatment for hepatocellular carcinoma
- Liver-directed treatment for metastatic colorectal cancer
The research profile also includes perioperative management for high-risk resectable hepatobiliary tumors.
Anal squamous cell carcinoma and other gastrointestinal malignancies
Additional activity extends to locally advanced anal squamous cell carcinoma and selected metastatic gastrointestinal cancers, including esophageal and stomach malignancies.
- Chemoradiotherapy strategies in anal cancer
- Multimodal treatment for advanced gastrointestinal tumors
- Immunotherapy combinations across digestive oncology
These studies broaden the sponsor’s activity across digestive system oncology beyond the main colorectal and upper gastrointestinal programs.
